ARTICLE | Company News
Merck grants anti-infectives newco rights to antibiotic programs
February 2, 2018 8:38 PM UTC
Merck & Co. Inc. (NYSE:MRK) granted new anti-infectives company Prokaryotics Inc. (Union, N.J.) worldwide rights to develop, manufacture and commercialize a group of early preclinical antibiotic programs targeting Gram-negative and Gram-positive bacterial cell envelope enzymes. Prokaryotics VP of Business Development Pamela Demain told BioCentury that the company plans to develop antibiotics with “novel mechanisms of action.”
She said the deal includes royalties and milestones, but declined to provide further terms...